
Understanding the First Sale Rule in U.S. Customs Law
This story originally appeared on Due
The first sale rule is a significant provision in U.S. customs law, offering importers a strategic advantage when calculating duties on imported goods. This legal concept allows businesses to base their duty calculations on the lowest cost of goods in a multi-tiered transaction, potentially resulting in substantial savings for companies engaged in international trade.
Under standard customs procedures, importers typically pay duties based on the price they pay to acquire goods from foreign suppliers. However, the first sale rule creates an alternative pathway to reduce these costs in specific supply chain structures significantly.
How the First Sale Rule Works
The rule applies to multi-tiered transaction chains where goods change hands multiple times before reaching the U.S. importer. In such scenarios, the rule permits importers to calculate duties based on the 'first sale' price—the amount paid in the initial transaction between the manufacturer and the middleman—rather than the higher price paid by the U.S. importer to the middleman.
For example, if a manufacturer in Asia sells products to a trading company for $80 per unit, and that trading company then sells to a U.S. importer for $100 per unit, the first sale rule would allow duties to be calculated on the $80 price rather than the $100 price.
This calculation method can create significant savings, especially for high-volume importers or those dealing with products with higher duty rates.
Requirements for Using the First Sale Rule
Importers seeking to take advantage of this provision must meet several key requirements:
The initial sale must be a genuine 'arm's length transaction' between unrelated parties
The goods must be destined for export to the United States at the time of the first sale
The importer must maintain detailed documentation proving the transaction values
The middleman must act as more than just a paper company, adding real value to the transaction
Customs authorities scrutinize first sale claims, requiring importers to provide substantial evidence supporting their valuation method. This typically includes sales contracts, purchase orders, invoices, proof of payment, and other documentation establishing the legitimacy of the transaction chain.
Strategic Importance for Importers
The first sale rule represents a valuable duty-saving opportunity for businesses with complex global supply chains. When properly implemented, this strategy can reduce customs costs by 10-20% or more for companies importing high-duty items or dealing in large volumes.
The savings can be dramatic,' notes one trade attorney who regularly advises clients on customs matters. For companies importing millions of dollars in goods annually, even a slight percentage reduction in duty rates translates to a substantial bottom-line impact.
The rule has gained increased attention recently as tariff rates have risen on many products, particularly those from China. As companies face growing pressure to control supply chain costs, customs strategies like the first sale rule have become more central to financial planning.
Despite its advantages, the first sale rule remains underutilized by many importers due to its documentation requirements and the need for careful supply chain structuring. Companies considering this approach should work with customs experts to ensure compliance with all regulatory requirements while maximizing potential savings.
The post Understanding the First Sale Rule in U.S. Customs Law appeared first on Due.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
In South Korea's 'apple county', farmers beg not to be sacrificed for US trade deal
By Hyunjoo Jin CHEONGSONG, South Korea (Reuters) -The apples grown in the South Korean county of Cheongsong in the country's southeast are so renowned for their flavour that they are often given out in neatly-packaged gift boxes during national holidays. But apple farmers, who account for about a third of the roughly 14,000 households in the sleepy rural area, worry that their way of life could be under threat from an influx of cheap U.S. imports. Fanning concerns, South Korea's trade minister suggested last week that Seoul could make concessions on some agricultural imports, although he said sensitive items should be protected, as part of any deal to eliminate or reduce punishing U.S. tariffs on cars, steel and other key exports. "U.S. apples are very cheap. We can't compete with them," said Shim Chun-taek, a third-generation farmer who has been growing apples for two decades. He now fears South Korean farmers risk being sacrificed to appease the U.S. and support the country's manufacturing sector. The United States has long called for better market access for its farm products from beef to apples and potatoes. U.S. President Donald Trump in April slammed steep tariffs on rice in South Korea and Japan. South Korea has taken steps to open its market and is now the top buyer of U.S. beef and the sixth-biggest destination for U.S. agricultural exports overall. Still, Washington has complained about persistent non-tariff barriers. South Korea's quarantine agency is still reviewing U.S. market access requests for apples more than 30 years after they were filed, sparking calls by Washington to expedite the approval process for a range of fruits and potatoes. SURGING PRICES Any opening up of the sector would increase pressure on apple farmers already wrestling with a host of problems, from climate change to an ageing population and wildfires, which have led to rising costs, smaller harvests, and higher prices. Bank of Korea governor Rhee Chang-yong last year said runaway prices of apples and other farm goods were contributing to inflation and that there was a need to consider more imports. The central bank noted South Korea's grocery prices were higher than the average for OECD countries, with apple prices nearly three times higher than the OECD average. "I think it is difficult to justify absolute protection to certain agriculture sectors simply because of its high sensitivity," said Choi Seok-young, a former chief negotiator for the Korea-U.S. free trade deal. It was hard to view the delayed quarantine process as "rational based on science and international norms," added Choi, who is now a senior adviser for law firm Lee & Ko. Agriculture has emerged as one of the sticking points in U.S. trade talks with South Korea and Japan, after countries such as Indonesia and Britain agreed to allow more agricultural imports from the U.S. in recent trade deals. Seoul has long restricted shipments of U.S. beef from cattle older than 30 months. Massive protests from South Koreans worried about safety due to mad cow disease followed a 2008 agreement with the United States to lift the restrictions. Shim, 48, who wakes at 3 a.m. every morning to work on his orchards, said it would be impossible to find alternative crops to grow in the mountainous area. The tariff talks have already fuelled protests from farmers' groups. There could be more to come. "We oppose the imports of apples no matter what," Youn Kyung-hee, mayor of Cheongsong county, told Reuters, adding that people will not "sit still" if Seoul opens up the market. ($1 = 1,391.1000 won) Sign in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
KIOXIA Announces Industry's First 245.76 TB NVMe SSD Built for the Demands of Generative AI Environments
KIOXIA LC9 Series Becomes the Highest Capacity PCIe 5.0 Enterprise SSD; Features 32-die Stack BiCS FLASH QLC 3D Flash Memory SAN JOSE, Calif., July 22, 2025--(BUSINESS WIRE)--KIOXIA America, Inc. has expanded its high-capacity KIOXIA LC9 Series enterprise SSD lineup by introducing the industry's first1 245.76 terabyte (TB)2 NVMe™ SSD in a 2.5-inch and Enterprise and Datacenter Standard Form Factor (EDSFF) E3.L form factor. This new capacity and form factor option complements the previously announced 122.88 TB (2.5-inch) model and is purpose-built for the performance and efficiency demands of generative AI environments. Generative AI places unique demands on storage, including the need to store vast datasets for training large language models (LLMs), and to create embeddings and vector databases that support inference through retrieval augmented generation (RAG). These workloads require storage solutions with large capacity, high speed, and exceptional power efficiency. Featuring a 32-die stack of 2 terabit (Tb)3 BiCS FLASH™ QLC 3D flash memory with innovative CBA (CMOS directly Bonded to Array) technology, KIOXIA LC9 Series SSDs deliver the speed, scale, and density required to support the next wave of AI-centric workloads. This combination of advanced memory architecture and CBA technology enables 8 TB3 in a small 154 BGA package – also an industry first1. This milestone was made possible with advancements in Kioxia's high-precision wafer processing, material design, and wire bonding technologies. KIOXIA LC9 Series SSDs are well-suited for data lakes, where massive data ingestion and rapid processing are essential. Unlike HDDs, which often bottleneck performance and leave costly GPUs underutilized, KIOXIA LC9 Series SSDs enable dense storage in a compact footprint. By delivering up to 245.76 TB, each drive can replace multiple power-hungry HDDs, offering superior performance, lower overall power consumption, fewer drive slots used, and more efficient cooling, which would significantly lower total cost of ownership (TCO). KIOXIA LC9 Series SSDs Features Include: Up to 245.76 TB in 2.5-inch and E3.L form factors Up to 122.88 TB available in 2.5-inch and E3.S form factors Designed to PCIe® 5.0 (max. 128 GT/s Gen5 single x4, dual x2), NVMe 2.0, and NVMe-MI™ 1.2c specifications Open Compute Project (OCP) Datacenter NVMe SSD specification v2.5 support (not all requirements) Flexible Data Placement (FDP) support to minimize write amplification and extend SSD lifespan4 Security options: SIE, SED, FIPS SED CNSA 2.0 signing algorithm adopted5, designed with future quantum security standards in mind "KIOXIA has a long history of advancing flash storage, and the KIOXIA LC9 Series continues that legacy by setting a new benchmark for capacity and innovation in the SSD space," said Neville Ichhaporia, senior vice president and general manager of the SSD business unit at KIOXIA America, Inc. "As generative AI reshapes data center architecture, we're delivering the kind of breakthrough technology that enables our customers to optimize their IT infrastructure investments - pushing boundaries in performance, efficiency, and scale." KIOXIA LC9 Series SSDs are now sampling to select customers and will be featured at the Future of Memory and Storage 2025 conference, taking place August 5–7 in Santa Clara. For more information, please visit and follow the company on X, formerly known as Twitter and LinkedIn®. About KIOXIA America, Inc. KIOXIA America, Inc. is the U.S.-based subsidiary of KIOXIA Corporation, a leading worldwide supplier of flash memory and solid-state drives (SSDs). From the invention of flash memory to today's breakthrough BiCS FLASH™ 3D technology, KIOXIA continues to pioneer innovative memory, SSD and software solutions that enrich people's lives and expand society's horizons. The company's innovative 3D flash memory technology, BiCS FLASH, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems. For more information, please visit © 2025 KIOXIA America, Inc. All rights reserved. Information in this press release, including product pricing and specifications, content of services, and contact information is current and believed to be accurate on the date of the announcement, but is subject to change without prior notice. Technical and application information contained here is subject to the most recent applicable KIOXIA product specifications. Notes: 1: As of July 21, 2025, based on Kioxia survey. 2: Definition of SSD capacity: Kioxia Corporation defines a kilobyte (KB) as 1,000 bytes, a megabyte (MB) as 1,000,000 bytes, a gigabyte (GB) as 1,000,000,000 bytes, a terabyte (TB) as 1,000,000,000,000 bytes, and a kibibyte (KiB) is 1,024 bytes. A computer operating system, however, reports storage capacity using powers of 2 for the definition of 1GB = 2^30 bytes = 1,073,741,824 bytes and 1TB = 2^40 bytes = 1,099,511,627,776 bytes and therefore shows less storage capacity. Available storage capacity (including examples of various media files) will vary based on file size, formatting, settings, software and operating system, and/or pre-installed software applications, or media content. Actual formatted capacity may vary. 3: The flash memory capacity is calculated as 1 terabit (1 Tb) = 1,099,511,627,776 (2^40) bits, and 1 terabyte (1 TB) = 1,099,511,627,776 (2^40) bytes. 4: For RocksDB purposes, Kioxia confirmed the Write Amplification Factor (WAF) is approximately 1.1 when using the FDP function with the plug-in (a function extension program released on the Kioxia GitHub account. 5: The KIOXIA LC9 Series SSD supports Leighton-Micali Signature (LMS) algorithm acknowledged by CNSA 2.0 (Commercial National Security Algorithm Suite 2.0) as a digital signature algorithm to prevent firmware tampering in preparation for threats to conventional cryptographic algorithms posed by quantum computers. Advanced Encryption Standard (AES-256) with a key length of 256 bits, which is the data encryption algorithm used in KIOXIA LC9 Series SSD, is also acknowledged by CNSA 2.0. 2.5-inch indicates the form factor of the SSD and not its physical size. Read and write speed may vary depending on various factors such as host devices, software (drivers, OS etc.), and read/write conditions. NVMe and NVMe-MI are registered or unregistered trademarks of NVM Express, Inc. in the United States and other countries. PCIe is a registered trademark of PCI-SIG. The OCP and OPEN COMPUTE PROJECT marks are owned by and used with the permission of the Open Compute Project Foundation. Sanitize Instant Erase (SIE), Self-Encrypting Drive (SED) and FIPS (Federal Information Processing Standards) SED security optional models are available. Security optional models are not available in all countries due to export and local regulations. LinkedIn is a trademark of LinkedIn Corporation and its affiliates in the United States and/or other countries. Other company names, product names and service names may be trademarks of third-party companies. View source version on Contacts Media Contact:Dena JacobsonLages & AssociatesTel: (949) 453-8080dena@ Company Contact: Mia CoolKIOXIA America, (408) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with an EGFR exon 19 deletion or L858R mutation with disease progression on or after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. DB-1310 is a novel ADC targeting HER3 developed using DualityBio's proprietary DITAC platform. In June 2025, Dr. Aaron E. Lisberg from the University of California, Los Angeles (UCLA) presented the first-in-human Phase I/IIa clinical trial data (NCT05785741) of DB-1310 in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The results demonstrated encouraging efficacy and a manageable safety profile in patients with advanced solid tumors who had failed standard therapies. Dr. Hua Mu, Global Chief Medical Officer of DualityBio, stated: "DB-1310 demonstrated encouraging clinical efficacy and manageable safety in patients with EGFRm nsqNSCLC and multiple solid tumors. It is noteworthy that preclinical investigations of DB-1310 in combination with EGFR TKIs and other anticancer agents have also demonstrated robust synergistic tumor suppression activity. We will spare no effort to accelerate the clinical development of DB-1310 and look forward to its potential, as a next-generation HER3 ADC, to become a novel therapeutic option for a broad population of cancer patients." About DualityBio Duality Biotherapeutics is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 17 countries, has enrolled over 2,000 patients for multiple clinical-stage ADC candidates. Additionally, DualityBio have established strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing bispecific ADCs, novel-payload ADCs, and autoimmune ADCs. For more information, please visit View original content to download multimedia: SOURCE Duality Biotherapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data